Medicaid Best Price and Its Implications on Cell and Gene Therapy Products
By Xcenda
The cell and gene therapy market is expected to grow in the future, and CMS is reviewing various options to respond to the unique challenges posed by these high-cost, yet potentially curative therapies.
Some possible solutions were included in the CMS final rule released in December 2020. The rule included provisions to help overcome existing barriers surrounding Medicaid Best Price for outcomes-based contracts, including long-term contracts lasting several years.
Download our new issue brief that explains this final rule and its impact on cell and gene therapies.
